search
Back to results

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Primary Purpose

Non-Hodgkin's Lymphoma

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Bortezomib + Rituximab
Rituximab
Sponsored by
Millennium Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-Hodgkin's Lymphoma focused on measuring B-cell Non-Hodgkin's Lymphoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study: Man or woman and age 18 years or older Diagnosis of follicular B-NHL of the following subtypes (World Health Organization [WHO] classification 1997): follicular lymphoma (FL) (Grades 1 and 2). Documented relapse or progression following prior antineoplastic treatment. New lesions or objective evidence of progression of existing lesions must document relapse or progression following the previous therapy. If any prior regimen included rituximab, the subject must have responded (complete response [CR], unconfirmed complete response [CRu], partial response [PR]), and the time to progression (TTP) from the first dose of rituximab must have been 6 months or more. At least 1 measurable tumor mass (greater than 1.5 cm in the longest dimension and greater than 1.0 cm in the short axis) that has not been previously irradiated, or has grown since previous irradiation In the opinion of the investigator the decision to initiate treatment is justified to manage the subject's lymphoma No active central nervous system lymphoma Eastern Cooperative Oncology Group [ECOG] status ≤ 2 Female subjects must be postmenopausal (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test at screening. Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. In countries where health authorities have approved the pharmacogenomic testing, subjects or their legally acceptable representatives must have signed a separate informed consent that they agree to participate in the genetic part and protein testing part of the study; participation in the genetic and protein testing component is mandatory for pharmacogenomics testing, but optional for serum protein testing and future testing. Exclusion Criteria: Potential subjects who meet any of the following criteria will be excluded from participating in the study: Diagnosed or treated for a malignancy other than NHL within 1 year of randomization, or who were previously diagnosed with a malignancy other than NHL and have any radiographic or biochemical marker evidence of malignancy. Subjects with completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy are not excluded. Clinical evidence of a transformation from indolent NHL to a more aggressive form of NHL. History of disallowed therapies: Prior treatment with VELCADE Antineoplastic (including unconjugated therapeutic antibodies), experimental, or radiation therapy within 3 weeks before randomization Nitrosoureas within 6 weeks before randomization Radioimmunoconjugates or toxin immunoconjugates within 10 weeks before randomization Stem cell transplant within 6 months before randomization Major surgery within 2 weeks before randomization Residual toxic effects of previous therapy or surgery of Grade 3 or worse Peripheral neuropathy or neuropathic pain of Grade 2 or worse Have received an experimental drug or used an experimental medical device within 21 days before the planned start of treatment. History of allergic reaction attributable to compounds containing boron or mannitol Known anaphylaxis or immunoglobulin E (IgE)-mediated hypersensitivity to murine proteins or to any component of rituximab including polysorbate 80 and sodium citrate dihydrate Concurrent treatment with another investigational agent Female subject who is pregnant or breast-feeding

Sites / Locations

  • East Alabama Medical Center
  • Central Hematology Oncology Medical Group, Inc
  • Comprehensive Blood and Cancer Center
  • Providence Saint Joseph Medical Center
  • St. Jude Heritage Medical Group
  • Wilshire Oncology Medical Group, Inc.
  • Pacific Shores Medical Group
  • University of Southern California
  • University of California, Los Angeles
  • North Valley Hematology Oncology
  • University of California, Irvine Medical Center
  • Ventura County Hematology-Oncology Specialists
  • Cancer Care Associates Medical Group, Inc.
  • Central Coast Medical Oncology Corporation
  • Norwalk Medical Group
  • Hematology Oncology PC
  • Integrated Community Oncology Network
  • Innovative Clinical Research of South Florida
  • Palm Beach Cancer Institute
  • Emory Univeersity ,Winship Cancer Institute
  • Suburban Hematology-Oncology Associates
  • Northwest Georgia Oncology Centers, P.C.
  • North Idaho Cancer Center
  • Investigative Clinical Research of Indiana
  • Siouxland Hematolgoy-Oncology Associates
  • Kansas City Cancer Center, LLC
  • Louisville Oncology
  • Hematology & Oncology Specialists
  • Sinai Hospital
  • Hattiesburg Clinic
  • Southeastern Medical Oncology Center
  • Oregon Health & Science University
  • Lancaster Cancer Center, Ltd.
  • The Western Pennsylvania Hospital
  • South Carolina Oncology Associates, PA
  • South Carolina Oncology Associates
  • Vanderbilt University
  • The Center for Cancer and Blood Disorders
  • Oncology Consultants
  • South Texas Oncology and Hematology
  • Medical College of Wisconsin Milwaukee
  • Higa San Martin
  • Hospital Professor Rodolfo Rossi
  • Centro Oncologico Integracion Regional
  • Princess Alexandra Hospital
  • Royal Adelaide Hospital
  • Peter MacCallum Cancer Institute
  • Alfred Hospital
  • Royal Melbourne Hospital
  • Fremantle Hospital
  • ULB Erasme
  • AZ Stuivenberg
  • AZ Sint Jan
  • Institute J. Bordet
  • Clinique Notre Dame
  • UZ Antwerpen - Universitair Ziekenhuis Antwerpen
  • UZ Gent - Universitair Ziekenhuis Gent
  • Virga Jesse Ziekenhuis, Dienst Hematologie
  • CHR La Citadelle
  • CHU Sart Tilman
  • Heilig Hart Roeselare
  • Servico de Oncologia do Hospital Sao Lucas da PUC do rio Grande do Sul
  • Instituto Nacional de Cancer
  • Hospital Brigadeiro
  • Faculdade de Medicina do ABC
  • Toronto Sunnybrook Regional Cancer Centre
  • University Health Network - Princess Margaret Hospital
  • Juravinski Cancer Centre
  • West China Hospital of Sichuan
  • Cancer Hospital (Institute), CAMS&PUMC
  • Beijing Cancer Hospital
  • Peking University People's Hospital
  • Affiliated Hospital of the Academy of Military Medical Sciences
  • Cancer Center, Sun Yat-Sen University
  • Peking University Third Hospital
  • RuiJin Hospital
  • Cancer Hospital - FuDan University
  • Bank of Cyprus Oncology Centre
  • Fakultni nemocnice Brno
  • Fakultni nemocnice Hradec Kralove
  • Fakultni nemocnice Olomouc
  • Vseobecna Fakultni Nemocnice
  • Paijat - Hameen Keskussairaala
  • Satakunnan Keskussairaala
  • Institut Bergonie
  • Clinique Victor Hugo
  • Hopital Claude Huriez
  • Centre Léon Bérard
  • Hopital Hotel Dieu
  • Service des Maladies due sang - Hopital haut Leveque
  • Centre Hospitalier Lyon Sud
  • Onkologische Schwerpunktpraxis
  • Universitatsklinikum Munster - Klinik fur Innere Medizin
  • Praxis für Hämetologie und Oncologie
  • Laiko General Hospital of Athens - 1st Internist Clinic - Hematology Department
  • University General Hospital Attikon - 2nd Department of Internal Medicine - Propedeutic & Research Institute
  • University Hospital of Patras - Department of Internal Medicine - Hematology Division
  • Debreceni Egyetem, Orvos- es Egeszsegtudomanyl Centrum, iii. Belgyogyaszati Klinika
  • Petz Aladar County Hospital
  • SZEgedi Tudomanyegyetem, II Belgyaszati Klinika
  • Institution Manipal Hospital
  • Postgraduate Institute of Medical Education and Research
  • Apollo Speciality Hospital
  • Nizam's Institute of Medical Sciences
  • SMS Medical College Hospital
  • Apollo Hospitals, Hyderabad Apollo Hospital Complex
  • Shirdi Saibaba Cancer Hospital
  • Department of Medical Oncology - Regional Cancer Centre
  • Regional Cancer Centre
  • Tata Memorial Centre
  • Soroka Medical Center
  • Rambam Medical Center
  • Hadassah Medical Center
  • Rabin Medical Center
  • Sorraski Tel Aviv Medical Center
  • Sheba Medical Center
  • Azienda Ospedaliero Universitaria di Bologna
  • Universita degli Studi di Perugia
  • Azienda Ospedallera Universitaria Policlinico Tor Vergata
  • Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista
  • Lung Cancer Center - National Cancer Center
  • Samsung Medical Center - Division of Hematology-Oncology, Department of Medicine
  • Hematology-Oncology Clinic, Center for Specific Organs Cancer - National Cancer Center
  • Samsung Medical Center - Department of Internal Medicine
  • Severance Hospital, Yonsei University College of Medicine
  • Asan Medical Center
  • Instituto Nacional De Ciencias Medicas Y Nutricion Salvador Zubiran
  • Instituto Nacional De Cancerologia Incan
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez UANL
  • Canterbury Health Laboratories
  • Klinika Hematologii Instytut Chorob Wewnetrznych
  • Klinika Hematologii CMUJ
  • Klinika Hematologii - Uniwersytetu Medycznego
  • Klinika Hematologii i Transplantologii Szpiku AM
  • Wojskowy Instytut Medyczny - Klinika Hematologii
  • Instytut Hematologii i Transfuzjologii
  • Klinika Hematologii AM
  • Klinika Nowotworow Ukladu Chlonnego
  • Katedra i Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku
  • Servico de Hematologia - Hospital de Dia - Hospital Da Universidade de Coimbra
  • Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E. - Departmento de Hematologia
  • Hospital de Dia de Hematologia - Hospital de Santa Maria E.P.E.
  • Serviço de Onco-hematologia, Instituto Português de Oncologia do Porto Franscisco Gentil, EPE
  • San Juan VA Medical Center
  • Spitalul clinic de urgenta
  • Institutul Clinic Fundeni Clinica de Hematologie
  • Spitalul Universitar de Urgenta Hematologie
  • Spitalul Clinic judetean de urgenta "Sf. Spiridon, Clinica Hematologie
  • Spitalul Clinic judetean de urgenta Mures
  • Arkhangelsk Region Clinical Hospital
  • Altay Regional Oncology Dispensary
  • Belgorod Regional Oncology Center
  • Cheliabinsk Regional Oncology Dispensary
  • Ekaterinburg City Clinical Hospital #7
  • 1st Republican Clinical Hospital of Udmurtia
  • Cancer Research Center
  • S.P. Botkin Moscow City Clinical Hospital
  • Moscow Region Clinical Research Institute
  • Semashko Central Clinical Hospital #2
  • City Oncology Hospital #62
  • Nizhniy Novgorod Region Clinical Hospital
  • Novosibirsk State Regional Clinical Hospital
  • Novosibirsk State Medical University
  • Medical Scientifical Radiology Center
  • Republikan Hospital named after V.A. Baranov
  • Saint Petersburg Pavlov State Medical University
  • Saratov State Medical University
  • St. Petersburg Clinical Research Institute of Hematology and Transfusiology
  • St. Petersburg City Hospital #31
  • Tomsk Research Oncology Institute
  • Republican Clinical Hospital of Bashkorkostan
  • FN F.D. Roosevelt - Oddelenie hematologie
  • Fakultna nemocnica L. Pasteura - Klinika hematologie a onkohematologie
  • Vychodoslovensky Onkologicky Ustave, a.s.
  • Martinska FN, Klinika hematologie a transfuziologie
  • GVI Oncology Clinical Trial Unit
  • Mary Potter Oncology Centre - Little Company of Mary Hospital
  • Chris Hani Baragwanath Hospital
  • East Cape Oncology Centre - St. Georges Hospital
  • Hospital Durans I Reynals - Institut Catala d'Oncologia
  • Hospital Germans Trias i Pujol Institut Catala d'Oncologia
  • Hospital Universitario La Paz
  • Hospital Universitario de Salamanca
  • Onkologiska kliniken Universitetssjukhuset
  • Centrum for Hematologi Karolinska University Hospital
  • Hematologiska kliniken M54 Karolinska University Hospital
  • King Chulalongkorn Memorial Hospital
  • Ramathibodi Hospital, Mahidol University
  • Siriraj Hospital, Mahidol University
  • Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University
  • Cherkassy Regional Oncology Dispensary
  • Dnepropetrovsk Regional Clinical Oncology Dispensary
  • Institute for Emergency and Urgent Medical Assistance named after V.K. Gusak of AMS of Ukraine
  • Khmelnitskiy Regional Hopsital
  • Kiev Center of Marrow Transplantaion
  • Krivoy Rog Oncology Dispensary
  • Institute of Blood Pathology and Transfusional Medicine of AMS of Ukraine, Lviv Clinical Hospital #5
  • Ukrainian Medical Stomatological Academy, Poltava Regional Dispensary
  • Crimean Republic Clinical Oncology Dispensary
  • Zhitomir Gerbachevsky Regional Clinical Hospital
  • Aberdeen Royal Infirmary - Department of Haematology
  • Addenbrooke's Hospital - Department of Haematology
  • University Hospital of Wales
  • Guy's & St. Thomas Hospital
  • Derriford Hospital - Department of Haematology
  • Taunton & Somerset Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Bortezomib + Rituximab

Rituximab

Arm Description

Outcomes

Primary Outcome Measures

Progression Free Survival
Progression free survival is defined as time from randomization to progressive disease or death due to any cause, whichever occurs first.

Secondary Outcome Measures

Overall Response Rate
Overall response rate is defined as Complete Response (CR) + Complete Response Unconfirmed (CRu) + Partial Response (PR) using International Working Group Criteria (IWGC) and Independent Radiographic Review results and clinical results. The IWGC CR requires complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms, and normalization of lactic dehydrogenase and bone marrow involvement. CRu requires more than 75% reduction in sum of product of nodes (SPD). PR requires moer than 50% reduction in SPD.

Full Information

First Posted
April 7, 2006
Last Updated
June 19, 2012
Sponsor
Millennium Pharmaceuticals, Inc.
Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
search

1. Study Identification

Unique Protocol Identification Number
NCT00312845
Brief Title
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Official Title
A Randomized, Open-Label, Multicenter Study of VELCADE With Rituximab or Rituximab Alone in Subjects With Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non-Hodgkin's Lymphoma
Study Type
Interventional

2. Study Status

Record Verification Date
June 2012
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
July 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Millennium Pharmaceuticals, Inc.
Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) who never received rituximab or who have previously responded to rituximab. This is an international study being conducted in the United States and in many countries around the world. A complete list of study locations is listed below.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Hodgkin's Lymphoma
Keywords
B-cell Non-Hodgkin's Lymphoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
676 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bortezomib + Rituximab
Arm Type
Experimental
Arm Title
Rituximab
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Bortezomib + Rituximab
Intervention Description
VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.
Intervention Type
Drug
Intervention Name(s)
Rituximab
Intervention Description
rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).
Primary Outcome Measure Information:
Title
Progression Free Survival
Description
Progression free survival is defined as time from randomization to progressive disease or death due to any cause, whichever occurs first.
Time Frame
Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months.
Secondary Outcome Measure Information:
Title
Overall Response Rate
Description
Overall response rate is defined as Complete Response (CR) + Complete Response Unconfirmed (CRu) + Partial Response (PR) using International Working Group Criteria (IWGC) and Independent Radiographic Review results and clinical results. The IWGC CR requires complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms, and normalization of lactic dehydrogenase and bone marrow involvement. CRu requires more than 75% reduction in sum of product of nodes (SPD). PR requires moer than 50% reduction in SPD.
Time Frame
Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study: Man or woman and age 18 years or older Diagnosis of follicular B-NHL of the following subtypes (World Health Organization [WHO] classification 1997): follicular lymphoma (FL) (Grades 1 and 2). Documented relapse or progression following prior antineoplastic treatment. New lesions or objective evidence of progression of existing lesions must document relapse or progression following the previous therapy. If any prior regimen included rituximab, the subject must have responded (complete response [CR], unconfirmed complete response [CRu], partial response [PR]), and the time to progression (TTP) from the first dose of rituximab must have been 6 months or more. At least 1 measurable tumor mass (greater than 1.5 cm in the longest dimension and greater than 1.0 cm in the short axis) that has not been previously irradiated, or has grown since previous irradiation In the opinion of the investigator the decision to initiate treatment is justified to manage the subject's lymphoma No active central nervous system lymphoma Eastern Cooperative Oncology Group [ECOG] status ≤ 2 Female subjects must be postmenopausal (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test at screening. Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. In countries where health authorities have approved the pharmacogenomic testing, subjects or their legally acceptable representatives must have signed a separate informed consent that they agree to participate in the genetic part and protein testing part of the study; participation in the genetic and protein testing component is mandatory for pharmacogenomics testing, but optional for serum protein testing and future testing. Exclusion Criteria: Potential subjects who meet any of the following criteria will be excluded from participating in the study: Diagnosed or treated for a malignancy other than NHL within 1 year of randomization, or who were previously diagnosed with a malignancy other than NHL and have any radiographic or biochemical marker evidence of malignancy. Subjects with completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy are not excluded. Clinical evidence of a transformation from indolent NHL to a more aggressive form of NHL. History of disallowed therapies: Prior treatment with VELCADE Antineoplastic (including unconjugated therapeutic antibodies), experimental, or radiation therapy within 3 weeks before randomization Nitrosoureas within 6 weeks before randomization Radioimmunoconjugates or toxin immunoconjugates within 10 weeks before randomization Stem cell transplant within 6 months before randomization Major surgery within 2 weeks before randomization Residual toxic effects of previous therapy or surgery of Grade 3 or worse Peripheral neuropathy or neuropathic pain of Grade 2 or worse Have received an experimental drug or used an experimental medical device within 21 days before the planned start of treatment. History of allergic reaction attributable to compounds containing boron or mannitol Known anaphylaxis or immunoglobulin E (IgE)-mediated hypersensitivity to murine proteins or to any component of rituximab including polysorbate 80 and sodium citrate dihydrate Concurrent treatment with another investigational agent Female subject who is pregnant or breast-feeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Millennium Pharmaceuticals, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
East Alabama Medical Center
City
Opelika,
State/Province
Alabama
Country
United States
Facility Name
Central Hematology Oncology Medical Group, Inc
City
Alhambra
State/Province
California
ZIP/Postal Code
91801
Country
United States
Facility Name
Comprehensive Blood and Cancer Center
City
Bakersfield
State/Province
California
ZIP/Postal Code
93309
Country
United States
Facility Name
Providence Saint Joseph Medical Center
City
Burbank
State/Province
California
ZIP/Postal Code
91505
Country
United States
Facility Name
St. Jude Heritage Medical Group
City
Fullerton
State/Province
California
ZIP/Postal Code
92835
Country
United States
Facility Name
Wilshire Oncology Medical Group, Inc.
City
La Verne
State/Province
California
ZIP/Postal Code
91790
Country
United States
Facility Name
Pacific Shores Medical Group
City
Long Beach
State/Province
California
ZIP/Postal Code
90813
Country
United States
Facility Name
University of Southern California
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Facility Name
University of California, Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
North Valley Hematology Oncology
City
Mission Hills
State/Province
California
ZIP/Postal Code
91345
Country
United States
Facility Name
University of California, Irvine Medical Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Ventura County Hematology-Oncology Specialists
City
Oxnard
State/Province
California
ZIP/Postal Code
93030
Country
United States
Facility Name
Cancer Care Associates Medical Group, Inc.
City
Redondo Beach
State/Province
California
ZIP/Postal Code
90277
Country
United States
Facility Name
Central Coast Medical Oncology Corporation
City
Santa Maria
State/Province
California
ZIP/Postal Code
93454
Country
United States
Facility Name
Norwalk Medical Group
City
Norwalk
State/Province
Connecticut
Country
United States
Facility Name
Hematology Oncology PC
City
Stamford
State/Province
Connecticut
Country
United States
Facility Name
Integrated Community Oncology Network
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
Innovative Clinical Research of South Florida
City
Miami
State/Province
Florida
Country
United States
Facility Name
Palm Beach Cancer Institute
City
West Palm Beach
State/Province
Florida
Country
United States
Facility Name
Emory Univeersity ,Winship Cancer Institute
City
Atlanta
State/Province
Georgia
Country
United States
Facility Name
Suburban Hematology-Oncology Associates
City
Lawrenceville
State/Province
Georgia
ZIP/Postal Code
30045
Country
United States
Facility Name
Northwest Georgia Oncology Centers, P.C.
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
North Idaho Cancer Center
City
Coeur D Alene
State/Province
Idaho
Country
United States
Facility Name
Investigative Clinical Research of Indiana
City
Indianapolis
State/Province
Indiana
Country
United States
Facility Name
Siouxland Hematolgoy-Oncology Associates
City
Sioux City
State/Province
Iowa
Country
United States
Facility Name
Kansas City Cancer Center, LLC
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66210
Country
United States
Facility Name
Louisville Oncology
City
Louisville
State/Province
Kentucky
Country
United States
Facility Name
Hematology & Oncology Specialists
City
Metairie
State/Province
Louisiana
Country
United States
Facility Name
Sinai Hospital
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
Hattiesburg Clinic
City
Hattesburg
State/Province
Missouri
Country
United States
Facility Name
Southeastern Medical Oncology Center
City
Goldsboro
State/Province
North Carolina
ZIP/Postal Code
27530
Country
United States
Facility Name
Oregon Health & Science University
City
Portland
State/Province
Oregon
Country
United States
Facility Name
Lancaster Cancer Center, Ltd.
City
Lancaster
State/Province
Pennsylvania
ZIP/Postal Code
17601
Country
United States
Facility Name
The Western Pennsylvania Hospital
City
Pittsburg
State/Province
Pennsylvania
Country
United States
Facility Name
South Carolina Oncology Associates, PA
City
Columbia
State/Province
South Carolina
ZIP/Postal Code
29210
Country
United States
Facility Name
South Carolina Oncology Associates
City
Columbia
State/Province
South Carolina
Country
United States
Facility Name
Vanderbilt University
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Facility Name
The Center for Cancer and Blood Disorders
City
Fort Worth
State/Province
Texas
Country
United States
Facility Name
Oncology Consultants
City
Houston
State/Province
Texas
ZIP/Postal Code
777024
Country
United States
Facility Name
South Texas Oncology and Hematology
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
Medical College of Wisconsin Milwaukee
City
Milwaukee
State/Province
Wisconsin
Country
United States
Facility Name
Higa San Martin
City
La Plata - Buenos Aires
Country
Argentina
Facility Name
Hospital Professor Rodolfo Rossi
City
La Plata - Buenos Aires
Country
Argentina
Facility Name
Centro Oncologico Integracion Regional
City
Mendoza
Country
Argentina
Facility Name
Princess Alexandra Hospital
City
Woolloongabba
State/Province
Queensland
ZIP/Postal Code
4102
Country
Australia
Facility Name
Royal Adelaide Hospital
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Facility Name
Peter MacCallum Cancer Institute
City
East Melbourne
State/Province
Victoria
ZIP/Postal Code
3002
Country
Australia
Facility Name
Alfred Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3004
Country
Australia
Facility Name
Royal Melbourne Hospital
City
Parkville
State/Province
Victoria
ZIP/Postal Code
3050
Country
Australia
Facility Name
Fremantle Hospital
City
Fremantle
State/Province
Western Australia
ZIP/Postal Code
6160
Country
Australia
Facility Name
ULB Erasme
City
Anderlecht
ZIP/Postal Code
1070
Country
Belgium
Facility Name
AZ Stuivenberg
City
Antwerpen
ZIP/Postal Code
2060
Country
Belgium
Facility Name
AZ Sint Jan
City
Brugge
ZIP/Postal Code
8000
Country
Belgium
Facility Name
Institute J. Bordet
City
Bruxelles
ZIP/Postal Code
1000
Country
Belgium
Facility Name
Clinique Notre Dame
City
Charleroi
ZIP/Postal Code
6000
Country
Belgium
Facility Name
UZ Antwerpen - Universitair Ziekenhuis Antwerpen
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
Facility Name
UZ Gent - Universitair Ziekenhuis Gent
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Virga Jesse Ziekenhuis, Dienst Hematologie
City
Hasselt
ZIP/Postal Code
3500
Country
Belgium
Facility Name
CHR La Citadelle
City
Liege
ZIP/Postal Code
4000
Country
Belgium
Facility Name
CHU Sart Tilman
City
Liege
ZIP/Postal Code
4000
Country
Belgium
Facility Name
Heilig Hart Roeselare
City
Roeselare
ZIP/Postal Code
8800
Country
Belgium
Facility Name
Servico de Oncologia do Hospital Sao Lucas da PUC do rio Grande do Sul
City
Porto Alegre
State/Province
Rio Grande do Sul
ZIP/Postal Code
90610-00
Country
Brazil
Facility Name
Instituto Nacional de Cancer
City
Rio de Janeiro
ZIP/Postal Code
20231-050
Country
Brazil
Facility Name
Hospital Brigadeiro
City
Sao Paulo
ZIP/Postal Code
01404-901
Country
Brazil
Facility Name
Faculdade de Medicina do ABC
City
Sao Paulo
ZIP/Postal Code
09060-650
Country
Brazil
Facility Name
Toronto Sunnybrook Regional Cancer Centre
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
University Health Network - Princess Margaret Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Juravinski Cancer Centre
City
Hamilton
Country
Canada
Facility Name
West China Hospital of Sichuan
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Facility Name
Cancer Hospital (Institute), CAMS&PUMC
City
Beijing
ZIP/Postal Code
100021
Country
China
Facility Name
Beijing Cancer Hospital
City
Beijing
ZIP/Postal Code
100036
Country
China
Facility Name
Peking University People's Hospital
City
Beijing
ZIP/Postal Code
100044
Country
China
Facility Name
Affiliated Hospital of the Academy of Military Medical Sciences
City
Beijing
ZIP/Postal Code
100071
Country
China
Facility Name
Cancer Center, Sun Yat-Sen University
City
Guangzhou
ZIP/Postal Code
510060
Country
China
Facility Name
Peking University Third Hospital
City
Haidian District Beijing
ZIP/Postal Code
100083
Country
China
Facility Name
RuiJin Hospital
City
Shanghai
ZIP/Postal Code
200025
Country
China
Facility Name
Cancer Hospital - FuDan University
City
Shanghai
ZIP/Postal Code
200032
Country
China
Facility Name
Bank of Cyprus Oncology Centre
City
Nikosia
ZIP/Postal Code
2006
Country
Cyprus
Facility Name
Fakultni nemocnice Brno
City
Brno
ZIP/Postal Code
625 00
Country
Czech Republic
Facility Name
Fakultni nemocnice Hradec Kralove
City
Hradec Kralove
ZIP/Postal Code
500 05
Country
Czech Republic
Facility Name
Fakultni nemocnice Olomouc
City
Olomouc
ZIP/Postal Code
775 20
Country
Czech Republic
Facility Name
Vseobecna Fakultni Nemocnice
City
Praha
ZIP/Postal Code
2
Country
Czech Republic
Facility Name
Paijat - Hameen Keskussairaala
City
Lahti
ZIP/Postal Code
15850
Country
Finland
Facility Name
Satakunnan Keskussairaala
City
Pori
ZIP/Postal Code
28500
Country
Finland
Facility Name
Institut Bergonie
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Facility Name
Clinique Victor Hugo
City
Le Mans
ZIP/Postal Code
72015
Country
France
Facility Name
Hopital Claude Huriez
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Centre Léon Bérard
City
Lyon
ZIP/Postal Code
69373
Country
France
Facility Name
Hopital Hotel Dieu
City
Nantes
ZIP/Postal Code
44098
Country
France
Facility Name
Service des Maladies due sang - Hopital haut Leveque
City
Pessac
ZIP/Postal Code
33604
Country
France
Facility Name
Centre Hospitalier Lyon Sud
City
Pierre Benite
ZIP/Postal Code
69495
Country
France
Facility Name
Onkologische Schwerpunktpraxis
City
Herrsching
ZIP/Postal Code
82211
Country
Germany
Facility Name
Universitatsklinikum Munster - Klinik fur Innere Medizin
City
Munster
Country
Germany
Facility Name
Praxis für Hämetologie und Oncologie
City
Würzburg
ZIP/Postal Code
97070
Country
Germany
Facility Name
Laiko General Hospital of Athens - 1st Internist Clinic - Hematology Department
City
Athens
ZIP/Postal Code
11527
Country
Greece
Facility Name
University General Hospital Attikon - 2nd Department of Internal Medicine - Propedeutic & Research Institute
City
Athens
ZIP/Postal Code
12462
Country
Greece
Facility Name
University Hospital of Patras - Department of Internal Medicine - Hematology Division
City
Rio Patras
ZIP/Postal Code
26500
Country
Greece
Facility Name
Debreceni Egyetem, Orvos- es Egeszsegtudomanyl Centrum, iii. Belgyogyaszati Klinika
City
Debrecen
ZIP/Postal Code
H-4004
Country
Hungary
Facility Name
Petz Aladar County Hospital
City
Gyor
ZIP/Postal Code
9024
Country
Hungary
Facility Name
SZEgedi Tudomanyegyetem, II Belgyaszati Klinika
City
Szeged
ZIP/Postal Code
H-6720
Country
Hungary
Facility Name
Institution Manipal Hospital
City
Bangalore
Country
India
Facility Name
Postgraduate Institute of Medical Education and Research
City
Chandigarh
ZIP/Postal Code
160 012
Country
India
Facility Name
Apollo Speciality Hospital
City
Chennai
ZIP/Postal Code
6000035
Country
India
Facility Name
Nizam's Institute of Medical Sciences
City
Hyderabaad
ZIP/Postal Code
500 082
Country
India
Facility Name
SMS Medical College Hospital
City
Jaipur
ZIP/Postal Code
302 004
Country
India
Facility Name
Apollo Hospitals, Hyderabad Apollo Hospital Complex
City
Jubilee Hills
Country
India
Facility Name
Shirdi Saibaba Cancer Hospital
City
Karnataka
ZIP/Postal Code
576 104
Country
India
Facility Name
Department of Medical Oncology - Regional Cancer Centre
City
Kerala
Country
India
Facility Name
Regional Cancer Centre
City
Kerala
Country
India
Facility Name
Tata Memorial Centre
City
Mumbai
ZIP/Postal Code
400 012
Country
India
Facility Name
Soroka Medical Center
City
Beer Sheva
Country
Israel
Facility Name
Rambam Medical Center
City
Haifa
Country
Israel
Facility Name
Hadassah Medical Center
City
Jerusalem
Country
Israel
Facility Name
Rabin Medical Center
City
Petah Tikva
Country
Israel
Facility Name
Sorraski Tel Aviv Medical Center
City
Tel Aviv
Country
Israel
Facility Name
Sheba Medical Center
City
Tel HaShomer
Country
Israel
Facility Name
Azienda Ospedaliero Universitaria di Bologna
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Facility Name
Universita degli Studi di Perugia
City
Perugia
ZIP/Postal Code
06122
Country
Italy
Facility Name
Azienda Ospedallera Universitaria Policlinico Tor Vergata
City
Roma
ZIP/Postal Code
00133
Country
Italy
Facility Name
Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista
City
Torino
ZIP/Postal Code
10126
Country
Italy
Facility Name
Lung Cancer Center - National Cancer Center
City
Gyeonggi-Do
ZIP/Postal Code
411-769
Country
Korea, Republic of
Facility Name
Samsung Medical Center - Division of Hematology-Oncology, Department of Medicine
City
Ilmon-Dong, Kangnam-Ku, Seoul
ZIP/Postal Code
135-710
Country
Korea, Republic of
Facility Name
Hematology-Oncology Clinic, Center for Specific Organs Cancer - National Cancer Center
City
Ilsandong-Gu, Goyang-Si, and Gyeonggi-Do
ZIP/Postal Code
410-769
Country
Korea, Republic of
Facility Name
Samsung Medical Center - Department of Internal Medicine
City
Ilwon dong, Kangnam-Ku, Seoul
ZIP/Postal Code
135-710
Country
Korea, Republic of
Facility Name
Severance Hospital, Yonsei University College of Medicine
City
Seoul
ZIP/Postal Code
120-752
Country
Korea, Republic of
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
138-736
Country
Korea, Republic of
Facility Name
Instituto Nacional De Ciencias Medicas Y Nutricion Salvador Zubiran
City
Delagacion Tlalpan
ZIP/Postal Code
14000
Country
Mexico
Facility Name
Instituto Nacional De Cancerologia Incan
City
Delagacion Tlalpan
ZIP/Postal Code
14080
Country
Mexico
Facility Name
Hospital Universitario Dr. Jose Eleuterio Gonzalez UANL
City
Monterrey, Nuevo leon
ZIP/Postal Code
64460
Country
Mexico
Facility Name
Canterbury Health Laboratories
City
Christchurch
Country
New Zealand
Facility Name
Klinika Hematologii Instytut Chorob Wewnetrznych
City
Gdansk
ZIP/Postal Code
80-952
Country
Poland
Facility Name
Klinika Hematologii CMUJ
City
Krakow
ZIP/Postal Code
31-501
Country
Poland
Facility Name
Klinika Hematologii - Uniwersytetu Medycznego
City
Lodz
ZIP/Postal Code
93-510
Country
Poland
Facility Name
Klinika Hematologii i Transplantologii Szpiku AM
City
Lublin
ZIP/Postal Code
20-081
Country
Poland
Facility Name
Wojskowy Instytut Medyczny - Klinika Hematologii
City
Warsawa
ZIP/Postal Code
00-909
Country
Poland
Facility Name
Instytut Hematologii i Transfuzjologii
City
Warszawa
ZIP/Postal Code
00-957
Country
Poland
Facility Name
Klinika Hematologii AM
City
Warszawa
ZIP/Postal Code
02-097
Country
Poland
Facility Name
Klinika Nowotworow Ukladu Chlonnego
City
Warszawa
ZIP/Postal Code
02-781
Country
Poland
Facility Name
Katedra i Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku
City
Wroclaw
ZIP/Postal Code
50-367
Country
Poland
Facility Name
Servico de Hematologia - Hospital de Dia - Hospital Da Universidade de Coimbra
City
Coimbra
ZIP/Postal Code
3000-075
Country
Portugal
Facility Name
Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E. - Departmento de Hematologia
City
Lisboa
ZIP/Postal Code
1099-023
Country
Portugal
Facility Name
Hospital de Dia de Hematologia - Hospital de Santa Maria E.P.E.
City
Lisboa
ZIP/Postal Code
1649-035
Country
Portugal
Facility Name
Serviço de Onco-hematologia, Instituto Português de Oncologia do Porto Franscisco Gentil, EPE
City
Porto
ZIP/Postal Code
4200-072
Country
Portugal
Facility Name
San Juan VA Medical Center
City
San Juan
ZIP/Postal Code
00921
Country
Puerto Rico
Facility Name
Spitalul clinic de urgenta
City
Brasov
Country
Romania
Facility Name
Institutul Clinic Fundeni Clinica de Hematologie
City
Bucuresti
Country
Romania
Facility Name
Spitalul Universitar de Urgenta Hematologie
City
Bucuresti
Country
Romania
Facility Name
Spitalul Clinic judetean de urgenta "Sf. Spiridon, Clinica Hematologie
City
Iasi
Country
Romania
Facility Name
Spitalul Clinic judetean de urgenta Mures
City
Targu Mures
Country
Romania
Facility Name
Arkhangelsk Region Clinical Hospital
City
Arghangelsk
ZIP/Postal Code
163045
Country
Russian Federation
Facility Name
Altay Regional Oncology Dispensary
City
Barnaul
ZIP/Postal Code
656049
Country
Russian Federation
Facility Name
Belgorod Regional Oncology Center
City
Belgorod
ZIP/Postal Code
308010
Country
Russian Federation
Facility Name
Cheliabinsk Regional Oncology Dispensary
City
Cheliabinsk
ZIP/Postal Code
454087
Country
Russian Federation
Facility Name
Ekaterinburg City Clinical Hospital #7
City
Ekaterinburg
ZIP/Postal Code
620137
Country
Russian Federation
Facility Name
1st Republican Clinical Hospital of Udmurtia
City
Izhevsk
ZIP/Postal Code
426039
Country
Russian Federation
Facility Name
Cancer Research Center
City
Moscow
ZIP/Postal Code
115478
Country
Russian Federation
Facility Name
S.P. Botkin Moscow City Clinical Hospital
City
Moscow
ZIP/Postal Code
125101
Country
Russian Federation
Facility Name
Moscow Region Clinical Research Institute
City
Moscow
ZIP/Postal Code
129110
Country
Russian Federation
Facility Name
Semashko Central Clinical Hospital #2
City
Moscow
ZIP/Postal Code
129128
Country
Russian Federation
Facility Name
City Oncology Hospital #62
City
Moscow
ZIP/Postal Code
143423
Country
Russian Federation
Facility Name
Nizhniy Novgorod Region Clinical Hospital
City
Nizhniy Novgorod
ZIP/Postal Code
603129
Country
Russian Federation
Facility Name
Novosibirsk State Regional Clinical Hospital
City
Novosibirsk
ZIP/Postal Code
630087
Country
Russian Federation
Facility Name
Novosibirsk State Medical University
City
Novosibirsk
ZIP/Postal Code
630091
Country
Russian Federation
Facility Name
Medical Scientifical Radiology Center
City
Obninsk
ZIP/Postal Code
249020
Country
Russian Federation
Facility Name
Republikan Hospital named after V.A. Baranov
City
Petrozavodsk
ZIP/Postal Code
185019
Country
Russian Federation
Facility Name
Saint Petersburg Pavlov State Medical University
City
Saint Petersburg
ZIP/Postal Code
197022
Country
Russian Federation
Facility Name
Saratov State Medical University
City
Saratov
ZIP/Postal Code
410028
Country
Russian Federation
Facility Name
St. Petersburg Clinical Research Institute of Hematology and Transfusiology
City
St. Petersburg
ZIP/Postal Code
191024
Country
Russian Federation
Facility Name
St. Petersburg City Hospital #31
City
St. Petersburg
ZIP/Postal Code
197110
Country
Russian Federation
Facility Name
Tomsk Research Oncology Institute
City
Tomsk
ZIP/Postal Code
634028
Country
Russian Federation
Facility Name
Republican Clinical Hospital of Bashkorkostan
City
Ufa
ZIP/Postal Code
450005
Country
Russian Federation
Facility Name
FN F.D. Roosevelt - Oddelenie hematologie
City
Banska Bysterica
ZIP/Postal Code
97517
Country
Slovakia
Facility Name
Fakultna nemocnica L. Pasteura - Klinika hematologie a onkohematologie
City
Kosice
ZIP/Postal Code
040 11
Country
Slovakia
Facility Name
Vychodoslovensky Onkologicky Ustave, a.s.
City
Kosice
ZIP/Postal Code
041 90
Country
Slovakia
Facility Name
Martinska FN, Klinika hematologie a transfuziologie
City
Martin
ZIP/Postal Code
036 59
Country
Slovakia
Facility Name
GVI Oncology Clinical Trial Unit
City
Panorama
State/Province
Cape Town
Country
South Africa
Facility Name
Mary Potter Oncology Centre - Little Company of Mary Hospital
City
Groenkloof, Pretoria
ZIP/Postal Code
0181
Country
South Africa
Facility Name
Chris Hani Baragwanath Hospital
City
Johannesburg
Country
South Africa
Facility Name
East Cape Oncology Centre - St. Georges Hospital
City
Port Elizabeth
Country
South Africa
Facility Name
Hospital Durans I Reynals - Institut Catala d'Oncologia
City
Barcelona
ZIP/Postal Code
08907
Country
Spain
Facility Name
Hospital Germans Trias i Pujol Institut Catala d'Oncologia
City
Barcelona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Hospital Universitario La Paz
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Hospital Universitario de Salamanca
City
Salamanca
ZIP/Postal Code
37007
Country
Spain
Facility Name
Onkologiska kliniken Universitetssjukhuset
City
Lund
Country
Sweden
Facility Name
Centrum for Hematologi Karolinska University Hospital
City
Stockholm
Country
Sweden
Facility Name
Hematologiska kliniken M54 Karolinska University Hospital
City
Stockholm
Country
Sweden
Facility Name
King Chulalongkorn Memorial Hospital
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
Facility Name
Ramathibodi Hospital, Mahidol University
City
Bangkok
ZIP/Postal Code
10400
Country
Thailand
Facility Name
Siriraj Hospital, Mahidol University
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand
Facility Name
Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University
City
Chiang Mai
ZIP/Postal Code
50200
Country
Thailand
Facility Name
Cherkassy Regional Oncology Dispensary
City
Cherkassy
ZIP/Postal Code
18009
Country
Ukraine
Facility Name
Dnepropetrovsk Regional Clinical Oncology Dispensary
City
Dnepropetrovsk
ZIP/Postal Code
46055
Country
Ukraine
Facility Name
Institute for Emergency and Urgent Medical Assistance named after V.K. Gusak of AMS of Ukraine
City
Donetsk
ZIP/Postal Code
83045
Country
Ukraine
Facility Name
Khmelnitskiy Regional Hopsital
City
Khmelnitsky
ZIP/Postal Code
29000
Country
Ukraine
Facility Name
Kiev Center of Marrow Transplantaion
City
Kiev
ZIP/Postal Code
03115
Country
Ukraine
Facility Name
Krivoy Rog Oncology Dispensary
City
Krivoy Rog
Country
Ukraine
Facility Name
Institute of Blood Pathology and Transfusional Medicine of AMS of Ukraine, Lviv Clinical Hospital #5
City
Lviv
ZIP/Postal Code
79044
Country
Ukraine
Facility Name
Ukrainian Medical Stomatological Academy, Poltava Regional Dispensary
City
Poltava
ZIP/Postal Code
36024
Country
Ukraine
Facility Name
Crimean Republic Clinical Oncology Dispensary
City
Simferopol
Country
Ukraine
Facility Name
Zhitomir Gerbachevsky Regional Clinical Hospital
City
Zhitomir
ZIP/Postal Code
10002
Country
Ukraine
Facility Name
Aberdeen Royal Infirmary - Department of Haematology
City
Aberdeen
Country
United Kingdom
Facility Name
Addenbrooke's Hospital - Department of Haematology
City
Cambridge
ZIP/Postal Code
CB2 2QQ
Country
United Kingdom
Facility Name
University Hospital of Wales
City
Cardiff
ZIP/Postal Code
CF14 4XN
Country
United Kingdom
Facility Name
Guy's & St. Thomas Hospital
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Facility Name
Derriford Hospital - Department of Haematology
City
Plymouth
ZIP/Postal Code
PL6 8DH
Country
United Kingdom
Facility Name
Taunton & Somerset Hospital
City
Taunton
ZIP/Postal Code
TA1 5DA
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
23088650
Citation
Zinzani PL, Khuageva NK, Wang H, Garicochea B, Walewski J, Van Hoof A, Soubeyran P, Caballero D, Buckstein R, Esseltine DL, Theocharous P, Enny C, Zhu E, Elsayed YA, Coiffier B. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naive or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. J Hematol Oncol. 2012 Oct 22;5:67. doi: 10.1186/1756-8722-5-67.
Results Reference
derived
PubMed Identifier
21724462
Citation
Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011 Aug;12(8):773-84. doi: 10.1016/S1470-2045(11)70150-4. Epub 2011 Jul 1.
Results Reference
derived

Learn more about this trial

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

We'll reach out to this number within 24 hrs